Celgene Corp (CELG.O)

CELG.O on Nasdaq

118.71USD
24 Apr 2015
Change (% chg)

$2.62 (+2.26%)
Prev Close
$116.09
Open
$115.94
Day's High
$120.72
Day's Low
$115.27
Volume
7,681,168
Avg. Vol
5,462,563
52-wk High
$129.06
52-wk Low
$68.38

CELG.O

Chart for CELG.O

About

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company’s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $95,038.12
Shares Outstanding(Mil.): 800.59
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 49.54 41.06 41.71
EPS (TTM): 2.40 -- --
ROI: 15.00 16.86 16.20
ROE: 33.02 17.36 17.00
Search Stocks

AstraZeneca insists Celgene deal about strategy, not cash

LONDON - AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.

24 Apr 2015

CORRECTED-AstraZeneca insists Celgene deal about strategy, not cash

LONDON, April 24 - AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.

24 Apr 2015

BRIEF-AstraZeneca open to acquisitions, smaller deals more likely

* CEO says no comment on Pfizer, completely focused on developing pipeline

24 Apr 2015

UPDATE 2-AstraZeneca looks beyond Nexium hit with new cancer deals

* Drugmaker reiterates financial forecasts for year (Adds analyst comment, latest shares)

24 Apr 2015

Morphosys CEO says MOR202 drug candidate still promising: newspaper

FRANKFURT - Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.

04 Apr 2015

Morphosys CEO says MOR202 drug candidate still promising - newspaper

FRANKFURT, April 5 - Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.

04 Apr 2015

Morphosys, Celgene end cooperation on MOR202 drug candidate

FRANKFURT - Morphosys and Celgene have agreed to end their cooperation on MOR202, but clinical trials of the drug candidate will continue, Morphosys said on Thursday.

26 Mar 2015

FDA approves new use for Celgene's cancer drug Revlimid

WASHINGTON - The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.

18 Feb 2015

U.S. FDA approves new use for Celgene's cancer drug Revlimid

WASHINGTON, Feb 18 - The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.

18 Feb 2015

Celgene says 2015 off to strong start; key growth drivers in place

- Celgene Corp on Thursday said early first quarter sales trends indicate the year is off to a strong start, and that it has growth drivers in place to meet or exceed its 2015 and long- term forecasts.

29 Jan 2015

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,247 -52.00
Eisai Co., Ltd (4523.T) ¥8,132 -104.00
Johnson & Johnson (JNJ.N) $101.08 +0.62
Pfizer Inc. (PFE.N) $35.27 -0.09
Novartis AG (NOVN.VX) CHF99.80 -0.80
Merck & Co., Inc. (MRK.N) $57.60 +0.09
Roche Holding Ltd. (ROG.VX) CHF276.60 -2.30
Abbott Laboratories (ABT.N) $48.32 -0.14
Sanofi SA (SASY.PA) €95.86 +0.51
AstraZeneca plc (AZN.L) 4,749.50p -80.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks